Description
Serrapeptase 130,000 SU gastro-resistant coating
Systemic enzymes are the key to your well-being and health. Yet, industrial food and exposure to environmental toxins force your body to overwork itself to make more and more enzymes to deal with the many complex reactions that are constantly taking place in your body.
The natural systemic enzyme serrapeptase, on the other hand, is a catalyst that stimulates and adjusts the body's recovery capabilities, with minimal side effects.
Indications
Serrapeptase is a powerful systemic enzyme that supports your entire body.
Advice for use
1-2 capsules 2 times a day 1/2 hour before meals.
Use
The registered trademark Peptizyme-SP® is an absolute guarantee of quality. It is important to follow the indicated dosage until results are visible. You can then switch to the maintenance dosage.
Serrapeptase can be used in conjunction with other systemic enzymes, such as Serracor NK.
Serrapeptase
Serrapeptase - also known as serratiopeptidase and serratia peptidase - is a highly active proteolytic enzyme derived from a species of bacteria originally found in the gut of silkworms. It is the Serratia mercesans bacterium that allows silkworms that have metamorphosed into butterflies to dissolve the threads of their cocoons and emerge. Of course, no worms or butterflies are sacrificed to produce serrapeptase from the Serratia bacterium. This one is cultivated alone to produce the enzyme by fermentation.
Peptizyme-SP® enteric-coated serrapeptase is the most potent form on the world market and has no equivalent as it contains 130,000 US, units of serrapeptase (it is also available in 80,000 units).
Enteric coating
It is a protective layer that coats the food supplements so that they remain intact during their passage through the stomach and are then absorbed in the small intestine. Systemic enzymes are proteins whose functional structure is altered or destroyed under extreme pH and temperature conditions. Without this coating, the enzymes would be denatured, and therefore unusable, long before they reach the bloodstream where their beneficial effects operate.
AST Enzymes' enteric-coated serrapeptase can pass through the highly acidic gastric environment without being degraded. This feature ensures intestinal absorption and systemic activity of the enzyme under the best conditions. Its gastric pH resistant coating naturally disintegrates in the alkaline environment of the intestine.
The relationship between US and IU
The activity of an enzyme is estimated by measuring its active units (U). For serrapeptase units, we speak of US. This is the only valid measurement for enzymes in general and serrapeptase in particular. Indeed, the measurement in IU (International Units) is a standard applied to vitamins and minerals, and defines the quantity of substance producing a specific biological effect.
Studies
The many and varied effects of serrapeptase on the body's immune response have been studied in detail.
References
- Panagariya A. and Sharma A. K. A preliminary trial of serratiopeptidase in patients with carpal tunnel syndrome. Journal of the Association of Indian Physicists, November 2000; 48 (11), p. 1130.
- Kee W. H., Tan S. L., Lee V. and Salmon Y. M. The treatment of breast engorgement with Serrapeptase (Danzen): a randomised double-blind controlled trial. Singapore, in Journal of Medicine, February 1989; 30 (1), pp. 48-54.
- 3. Gerngross H. and Fabian A. Reduction of postoperative swelling. Objective measurement of swelling of the upper ankle joint in treatment with serrapeptase, a prospective study (Germany), in Fortschr Med, 10 February 1989; 107 (4), pp. 67-68, 71-72. Esch PM.
- Mazzone A., Catalani M., Costanzo M., Drusian A., Mandoli A., Russo S., Guarini E. and Vesperini G. Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind, randomized trial versus placebo, in Journal Int Med Res., 1990; 18 (5), pp. 379-388
- Nakamura S., Hashimoto Y., Mikami M., Yamanaka E., Soma T., Hino M., Azuma A. and Kudoh S. Effect of the proteolytic enzyme serrapeptase in patients with chronic airway disease, in Respirology, September 2003; 8 (3), pp. 316-320.
- Mecikoglu M., Saygi B., Yildirim Y., Karadag-Saygi E., Ramadan S. S. and Esemenli T. The effect of proteolytic enzyme serratiopeptidase in the treatment of experimental implant-related infection, in Journal Bone Joint Surg Am, June 2006; 88 (6), pp. 1208-1214.
Alternatives
